Enlivex Therapeutics (ENLV)
(Delayed Data from NSDQ)
$1.55 USD
+0.04 (2.65%)
Updated Sep 18, 2024 04:00 PM ET
2-Buy of 5 2
F Value B Growth A Momentum B VGM
Brokerage Reports
0 items in cart
Enlivex Therapeutics Ltd. [ENLV]
Reports for Purchase
Showing records 1 - 20 ( 45 total )
Company: Enlivex Therapeutics Ltd.
Industry: Medical - Drugs
Equity Financing Complete; Multiple Clinical Updates; Modulating PT to $6
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Enlivex Therapeutics Ltd.
Industry: Medical - Drugs
Knee Osteoarthritis Clinical Program Advances; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Enlivex Therapeutics Ltd.
Industry: Medical - Drugs
Sepsis Phase 2 Data Mixed; More Data Catalysts Approach; Lowering PT to $7
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Enlivex Therapeutics Ltd.
Industry: Medical - Drugs
Allocetra Clinical Progress; Near-Term Data Catalyst; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Enlivex Therapeutics Ltd.
Industry: Medical - Drugs
Sepsis Phase 2 Trial Completes Enrollment; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Enlivex Therapeutics Ltd.
Industry: Medical - Drugs
3Q23 Financial Results Reported; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Enlivex Therapeutics Ltd.
Industry: Medical - Drugs
Strategic Reprioritization Extends Runway Through 2025; Lowering PT to $12
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Enlivex Therapeutics Ltd.
Industry: Medical - Drugs
First Patient Dosed Under Phase 2 Sepsis Amended Protocol; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Enlivex Therapeutics Ltd.
Industry: Medical - Drugs
Intellectual Property Estate Continues to Expand; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Enlivex Therapeutics Ltd.
Industry: Medical - Drugs
Clinical Progress Continues; 2022 Financial Results; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Enlivex Therapeutics Ltd.
Industry: Medical - Drugs
Spanish Agency Clearance for Allocetra Cancer Trial; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Enlivex Therapeutics Ltd.
Industry: Medical - Drugs
Oncology Program Granted Authorization to Continue; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Enlivex Therapeutics Ltd.
Industry: Medical - Drugs
Sepsis Trial Expansion; Oncology Programs Continue Progress; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Enlivex Therapeutics Ltd.
Industry: Medical - Drugs
Oncology-Focused Clinical Advances; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Enlivex Therapeutics Ltd.
Industry: Medical - Drugs
U.S. Patent Protection Enhanced; New Cancer Model Data; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Enlivex Therapeutics Ltd.
Industry: Medical - Drugs
Japanese Patent Application Allowed; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Enlivex Therapeutics Ltd.
Industry: Medical - Drugs
Oncology Programs Advancing; 2Q22 Financial Results; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Enlivex Therapeutics Ltd.
Industry: Medical - Drugs
First Proof-of-Concept Cancer Trial Starts; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Enlivex Therapeutics Ltd.
Industry: Medical - Drugs
Preclinical Data Support Allocetra Utility in Solid Tumors; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Enlivex Therapeutics Ltd.
Industry: Medical - Drugs
COVID-19 De-Prioritized; Clinical Timelines Revised; Reducing PT to $15
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R